English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
 Local TagsRelease HistoryDetailsSummary
  Human antibody RNase fusion protein targeting CD30+ lymphomas

Menzel, C., Schirrmann, T., Konthur, Z., Jostock, T., & Dübel, S. (2008). Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood, 111(7), 3830-3837. doi:10.1182/blood-2007-04-082768.

Item is

 

show all hide all

Basic

show hide
Item Permalink: https://hdl.handle.net/11858/00-001M-0000-0010-801D-D Version Permalink: https://hdl.handle.net/11858/00-001M-0000-0010-801E-B
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Menzel, Christian, Author
Schirrmann, Thomas, Author
Konthur, Zoltan1, Author
Jostock, Thomas, Author
Dübel, Stefan, Author
Affiliations:
1Max Planck Society, ou_persistent13              

Content

show
hide
Free keywords: -
 Abstract: Targeted RNases (TRs) are immunoenzymes with ribonucleases as cytotoxic effector domains, which are less immunogenic as plant or bacterial toxin components of classical immunotoxins. In this study, we show the generation and production of the first entirely human TR (huTR) directed against CD30+ lymphomas. The scFv-Fc-RNase construct was produced in human embryonic kidney (HEK) 293T cells, yielding up to 4 mg/L soluble protein after purification by protein A affinity chromatography. Size exclusion chromatography revealed a homodimer of the predicted molecular mass. Surface plasmon resonance analysis revealed an affinity to CD30 of KD of less than 1 nM for both the scFv-Fc and the scFv-Fc-RNase proteins. Internalization of the scFv-Fc-RNase protein by CD30+ Karpas-299 cells was demonstrated by confocal microscopy. Proliferation of the CD30+ lymphoma cell line Karpas-299 was strongly inhibited by CD30-specific huTR protein (IC50 = 3.3 nM). The huTR is a promising candidate for the immunotherapy of CD30+ lymphomas because of its expected low immunogenicity, good production yields, and potent effector function upon target cell binding and internalization. Its modular design is set to target other internalizing tumor antigens using different antibody domains.

Details

show
hide
Language(s): eng - English
 Dates: 2008-04-01
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: eDoc: 411195
DOI: 10.1182/blood-2007-04-082768
URI: http://bloodjournal.hematologylibrary.org/cgi/reprint/111/7/3830
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Blood
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 111 (7) Sequence Number: - Start / End Page: 3830 - 3837 Identifier: ISSN: 1528-0020